| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Eisai Inc. (Drs. Rogers and Friedhoff), Teaneck, NJ; the Indiana University School of Medicine (Dr. Farlow), Indianapolis, IN; Baylor College of Medicine (Dr. Doody), Houston, TX; and the Mount Sinai Medical Center (Dr. Mohs), New York, NY.
Address correspondence and reprint requests to Dr. L. T. Friedhoff, Eisai Inc., Glenpointe Centre West, 500 Frank W. Burr Blvd., Teaneck, NJ 07666-6741.
The efficacy and safety of donepezil as a treatment for patients with mild to moderate Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients were randomly assigned to treatment with placebo(n = 162), 5 mg/d donepezil (n = 154), or 10 mg/d donepezil (n = 157) for 24 weeks followed by a 6-week, single-blind placebo washout. The primary efficacy measures were the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) and the Clinician's Interview Based Assessment of Change-Plus (CIBIC plus), with the Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale-Sum of the Boxes (CDR-SB), and patient rated Quality of Life (QoL) used as secondary measures. Cognitive function, as measured by the ADAS-cog, was significantly improved in the 5- and 10-mg/d donepezil groups as compared with the placebo group at weeks 12, 18, and 24. Clinician's global ratings on the CIBIC plus also improved in both the 5- and 10-mg/d donepezil groups relative to placebo. At the end of the 6-week placebo washout phase, ADAS-cog scores and CIBIC plus ratings were not significantly different for the three groups. Significant treatment benefits were also observed consistently in both the 5- and 10-mg/d groups on the MMSE and the CDR-SB, but there was no consistent effect on the patient-rated QoL. Cholinergic side effects (primarily diarrhea, nausea, and vomiting) were reported more often in the 10-mg/d group than either the 5-mg/d or placebo groups. Side effects were transient and generally mild in severity. These data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.
*See the Appendix on page 144 for a listing of the members of the Donepezil Group.
Supported by Eisai Inc., Teaneck NJ, U.S.A. and Eisai Co. Ltd., Tokyo, Japan.
Received March 12, 1997. Accepted in final form August 20, 1997.
This article has been cited by other articles:
|
|
 |
|
  A. Qaseem, V. Snow, J. T. Cross Jr., M. A. Forciea, R. Hopkins Jr., P. Shekelle, A. Adelman, D. Mehr, K. Schellhase, D. Campos-Outcalt, et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians Ann Intern Med, March 4, 2008; 148(5): 370 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline Ann Intern Med, March 4, 2008; 148(5): 379 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bentley, J. Driver, and R. J. Dolan Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health Brain, February 1, 2008; 131(2): 409 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Caselli and R. Yaari Medical Management of Frontotemporal Dementia American Journal of Alzheimer's Disease and Other Dementias, January 1, 2008; 22(6): 489 - 498. [Abstract] [PDF]
|
|
|
|
 |
|
 J. R. Tinklenberg, H. C. Kraemer, K. Yaffe, L. Ross, J. Sheikh, J. W. Ashford, J. A. Yesavage, and J. L. Taylor Donepezil Treatment and Alzheimer Disease: Can the Results of Randomized Clinical Trials Be Applied to Alzheimer Disease Patients in Clinical Practice? Am J Geriatr Psychiatry, November 1, 2007; 15(11): 953 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mozayan and T. J. F. Lee Statins prevent cholinesterase inhibitor blockade of sympathetic {alpha}7-nAChR-mediated currents in rat superior cervical ganglion neurons Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1737 - H1744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Swanson and R. M. Carnahan Dementia and Comorbidities: An Overview of Diagnosis and Management Journal of Pharmacy Practice, August 1, 2007; 20(4): 296 - 317. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Matsuda Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT J. Nucl. Med., August 1, 2007; 48(8): 1289 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Rowland, J. Rigby, A. C. Harper, and R. Rowland Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol Advan. Psychiatr. Treat., May 1, 2007; 13(3): 178 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Chappell, C. Gonzales, J. Williams, M. M. Witte, R. C. Mohs, and R. Sperling AMPA potentiator treatment of cognitive deficits in Alzheimer disease Neurology, March 27, 2007; 68(13): 1008 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rozzini, B. V. Chilovi, E. Bertoletti, M. Conti, I. Delrio, M. Trabucchi, and A. Padovani Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study. American Journal of Alzheimer's Disease and Other Dementias, February 1, 2007; 22(1): 42 - 47. [Abstract] [PDF]
|
|
|
|
|
|
A. T. Blaszczyk and M. Mathys Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia Journal of Pharmacy Practice, February 1, 2007; 20(1): 13 - 28. [Abstract] [PDF]
|
|
|
|
|
|
J. F. Paskavitz, J. J. Gunstad, and J. E. Samuel Clock Drawing and Frontal Lobe Behavioral Effects of Memantine in Alzheimer's Disease: A Rater-Blinded Study American Journal of Alzheimer's Disease and Other Dementias, January 1, 2007; 21(6): 454 - 459. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Burns and J. O'Brien Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol, November 1, 2006; 20(6): 732 - 755. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M Ringman Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer's disease. Evid. Based Ment. Health, November 1, 2006; 9(4): 104 - 104. [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang Therapeutic approaches to Alzheimer's disease Brain, November 1, 2006; 129(11): 2840 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kaneko, H. Okano, and K. Sawamoto Role of the cholinergic system in regulating survival of newborn neurons in the adult mouse dentate gyrus and olfactory bulb. Genes Cells, October 1, 2006; 11(10): 1145 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lopez-Pousa, J. G. Olmo, J. V. Franch, A. T. Estrada, O. S. Cors, I. P. Nierga, and E. Gelada-Batlle Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age Ageing, July 1, 2006; 35(4): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gillette-Guyonnet, S. Andrieu, F. Cortes, F. Nourhashemi, C. Cantet, P.-J. Ousset, E. Reynish, H. Grandjean, and B. Vellas Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2006; 61(5): 516 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Bourgeois, F. Farzin, J. A. Brunberg, F. Tassone, P. Hagerman, L. Zhang, D. Hessl, and R. Hagerman Dementia With Mood Symptoms in a Fragile X Premutation Carrier With the Fragile X-Associated Tremor/Ataxia Syndrome: Clinical Intervention With Donepezil and Venlafaxine J Neuropsychiatry Clin Neurosci, May 1, 2006; 18(2): 171 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kazui, N. Hirono, M. Hashimoto, Y. Nakano, K. Matsumoto, Y. Takatsuki, E. Mori, Y. Ikejiri, and M. Takeda Symptoms Underlying Unawareness of Memory Impairment in Patients With Mild Alzheimer's Disease J Geriatr Psychiatry Neurol, March 1, 2006; 19(1): 3 - 12. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Marseille and D. H.S. Silverman Recognition and treatment of Alzheimer's disease: A case-based review American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 119 - 125. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Joshi and M. Parle Brahmi rasayana Improves Learning and Memory in Mice. Evid. Based Complement. Altern. Med., March 1, 2006; 3(1): 79 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Doyle, J. Frazier, T. J. Spencer, D. Geller, J. Biederman, and T. Wilens Donepezil in the Treatment of ADHD-Like Symptoms in Youths With Pervasive Developmental Disorder: A Case Series. J Atten Disord, February 1, 2006; 9(3): 543 - 549. [Abstract] [PDF]
|
|
|
|
|
|
T. T.J. Kircher, M. Erb, W. Grodd, and D. T. Leube Cortical Activation During Cholinesterase-Inhibitor Treatment in Alzheimer Disease: Preliminary Findings From a Pharmaco-fMRI Study Am J Geriatr Psychiatry, November 1, 2005; 13(11): 1006 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Simpson, D. Beavis, A. Leddy, S. Ball, and I. Johnson Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors Psychiatr. Bull., November 1, 2005; 29(11): 410 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Xiong, K. Yu, F. Gao, Y. Yan, and Z. Zhang Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial Clinical Trials, October 1, 2005; 2(5): 387 - 393. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Farlow Moderate to severe Alzheimer disease: Definition and clinical relevance Neurology, September 27, 2005; 65(6_suppl_3): S1 - S4. [Full Text]
|
|
|
|
|
|
H. H. Feldman and M. Woodward The staging and assessment of moderate to severe Alzheimer disease Neurology, September 27, 2005; 65(6_suppl_3): S10 - S17. [Abstract] [Full Text]
|
|
|
|
|
|
H. Fillit Cost consequences and cost benefits of treating patients with moderate to severe Alzheimer disease Neurology, September 27, 2005; 65(6_suppl_3): S31 - S33. [Full Text]
|
|
|
|
 |
|
 H. Kaduszkiewicz, T. Zimmermann, H.-P. Beck-Bornholdt, and H. van den Bussche Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials BMJ, August 6, 2005; 331(7512): 321 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Ravina, M Putt, A Siderowf, J T Farrar, M Gillespie, A Crawley, H H Fernandez, M M Trieschmann, S Reichwein, and T Simuni Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 934 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Petersen, R. G. Thomas, M. Grundman, D. Bennett, R. Doody, S. Ferris, D. Galasko, S. Jin, J. Kaye, A. Levey, et al. Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment N. Engl. J. Med., June 9, 2005; 352(23): 2379 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Vandenberghe and J Tournoy Cognitive aging and Alzheimer's disease Postgrad. Med. J., June 1, 2005; 81(956): 343 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hashimoto, H. Kazui, K. Matsumoto, Y. Nakano, M. Yasuda, and E. Mori Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer's Disease? Am J Psychiatry, April 1, 2005; 162(4): 676 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N I Bohnen, D I Kaufer, R Hendrickson, L S Ivanco, B J Lopresti, R A Koeppe, C C Meltzer, G Constantine, J G Davis, C A Mathis, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 315 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Ellis Cholinesterase Inhibitors in the Treatment of Dementia J Am Osteopath Assoc, March 1, 2005; 105(3): 145 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D Chiaravalloti, J. DeLuca, N. B Moore, and J. H Ricker Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial Multiple Sclerosis, February 1, 2005; 11(1): 58 - 68. [Abstract] [PDF]
|
|
|
|
|
|
C. H. Salmond, D. A. Chatfield, D. K. Menon, J. D. Pickard, and B. J. Sahakian Cognitive sequelae of head injury: involvement of basal forebrain and associated structures Brain, January 1, 2005; 128(1): 189 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Langa, N. L. Foster, and E. B. Larson Mixed Dementia: Emerging Concepts and Therapeutic Implications JAMA, December 15, 2004; 292(23): 2901 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Seltzer, P. Zolnouni, M. Nunez, R. Goldman, D. Kumar, J. Ieni, S. Richardson, and for the Donepezil "402" Study Group Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial Arch Neurol, December 1, 2004; 61(12): 1852 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins Donepezil improved memory in multiple sclerosis in a randomized clinical trial Neurology, November 9, 2004; 63(9): 1579 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohrui, N. Tomita, T. Sato-Nakagawa, T. Matsui, M. Maruyama, K. Niwa, H. Arai, and H. Sasaki Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression Neurology, October 12, 2004; 63(7): 1324 - 1325. [Full Text] [PDF]
|
|
|
|
 |
|
 A. P Periclou, D. Ventura, T. Sherman, N. Rao, and W. T Abramowitz Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil Ann. Pharmacother., September 1, 2004; 38(9): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Salloway, S. Ferris, A. Kluger, R. Goldman, T. Griesing, D. Kumar, and S. Richardson Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial Neurology, August 24, 2004; 63(4): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Ritchie, D. Ames, T. Clayton, and R. Lai Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease Am J Geriatr Psychiatry, August 1, 2004; 12(4): 358 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kenakin Allosteric Modulators: The New Generation of Receptor Antagonist Mol. Interv., August 1, 2004; 4(4): 222 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Cummings Alzheimer's Disease N. Engl. J. Med., July 1, 2004; 351(1): 56 - 67. [Full Text] [PDF]
|
|
|
|
|
|
K Rockwood Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Yasui-Furukori, H. Furukori, A. Kaneda, S. Kaneko, and T. Tateishi The Effects of Ginkgo biloba Extracts on the Pharmacokinetics and Pharmacodynamics of Donepezil J. Clin. Pharmacol., May 1, 2004; 44(5): 538 - 542. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. L. Cummings Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations Focus, April 1, 2004; 2(2): 239 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Beglinger, B. L. Gaydos, D. A. Kareken, O. Tangphao-Daniels, E. R. Siemers, and R. C. Mohs Neuropsychological Test Performance in Healthy Volunteers Before and After Donepezil Administration J Psychopharmacol, March 1, 2004; 18(1): 102 - 108. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Raskind, E. R. Peskind, L. Truyen, P. Kershaw, and C. V. Damaraju The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months: A Long-term Extension Trial Arch Neurol, February 1, 2004; 61(2): 252 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Reines, G. A. Block, J. C. Morris, G. Liu, M. L. Nessly, C. R. Lines, B. A. Norman, and C. C. Baranak Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology, January 13, 2004; 62(1): 66 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Ritchie, A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q.-X. Li, A. Tammer, et al. Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting A{beta} Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial Arch Neurol, December 1, 2003; 60(12): 1685 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. R. Krishnan, H. C. Charles, P. M. Doraiswamy, J. Mintzer, R. Weisler, X. Yu, C. Perdomo, J. R. Ieni, and S. Rogers Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease Am J Psychiatry, November 1, 2003; 160(11): 2003 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Black, G. C. Roman, D. S. Geldmacher, S. Salloway, J. Hecker, A. Burns, C. Perdomo, D. Kumar, and R. Pratt Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial Stroke, October 1, 2003; 34(10): 2323 - 2330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Lanctot, N. Herrmann, K. K. Yau, L. R. Khan, B. A. Liu, M. M. LouLou, and T. R. Einarson Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis Can. Med. Assoc. J., September 16, 2003; 169(6): 557 - 564. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. SPECTOR, L. THORGRIMSEN, B. WOODS, L. ROYAN, S. DAVIES, M. BUTTERWORTH, and M. ORRELL Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial The British Journal of Psychiatry, September 1, 2003; 183(3): 248 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wilkinson, R. Doody, R. Helme, K. Taubman, J. Mintzer, A. Kertesz, and R.D. Pratt Donepezil in vascular dementia: A randomized, placebo-controlled study Neurology, August 26, 2003; 61(4): 479 - 486. [Abstract] [Full Text]</ |
